<p>Geode Capital Management LLC 在最近向美國證券交易委員會提交的 13F 報告中表示，在第四季度將其在 Celcuity, Inc.（NASDAQ:CELC - 免費報告）股票中的持倉提高了 8.4%。該公司在本季度額外收購了 64,213 股後，持有 830,684 股 Celcuity 的股票。到最近一個季度末，Geode Capital Management LLC 擁有約 1.80% 的 Celcuity，價值 82,872,000 美元。</p>
<ul>
<li>你會希望在 2026 年之前購買的 3 只股票</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也對其在 CELC 的持倉進行了調整。EverSource Wealth Advisors LLC 在第四季度將其在 Celcuity 的股份增加了 1,329.2%。EverSource Wealth Advisors LLC 現在擁有 343 股該公司的股票，價值 34,000 美元，此前在此期間額外收購了 319 股。US Bancorp DE 在第三季度將其在 Celcuity 的股份增加了 25.4%。US Bancorp DE 現在擁有 706 股該公司的股票，價值 35,000 美元，此前在此期間額外收購了 143 股。BNP Paribas Financial Markets 在第二季度將其在 Celcuity 的股份增加了 78.9%。BNP Paribas Financial Markets 現在擁有 2,647 股該公司的股票，價值 35,000 美元，此前在此期間額外收購了 1,167 股。Ogorek Anthony Joseph NY ADV 在第四季度將其在 Celcuity 的股份增加了 19.7%。Ogorek Anthony Joseph NY ADV 現在擁有 662 股該公司的股票，價值 66,000 美元，此前在此期間額外收購了 109 股。最後，Tower Research Capital LLC TRC 在第二季度將其在 Celcuity 的股份增加了 211.2%。Tower Research Capital LLC TRC 現在擁有 5,549 股該公司的股票，價值 74,000 美元，此前在此期間額外收購了 3,766 股。機構投資者持有該公司 63.33% 的股票。</p>
<h2>Celcuity 關鍵新聞</h2>
<p>以下是本週影響 Celcuity 的關鍵新聞：</p>
<ul>
<li>積極情緒：HC Wainwright 維持對 Celcuity 的 <strong>買入</strong> 評級，並設定 <strong>145 美元的目標價</strong>，其長期預測仍暗示到 2028-2030 年具有顯著的盈利潛力。</li>
<li>中性情緒：該公司還宣佈了一項 <strong>增大至 5 億美元的可轉換高級票據發行，截止日期為 2032 年</strong>，這改善了開發資金，但也引發了對股東稀釋的擔憂。Celcuity 宣佈增大公共發行 0.250% 可轉換高級票據的定價，截止日期為 2032 年。</li>
<li>中性情緒：Celcuity 將其 <strong>第三階段 VIKTORIA-2</strong> 試驗擴展至包括內分泌敏感型乳腺癌患者，如果研究繼續順利推進，這一發展可能會擴大市場機會。Celcuity 擴展第三階段 VIKTORIA-2 試驗以包括內分泌敏感型乳腺癌患者。</li>
<li>消極情緒：HC Wainwright <strong>下調了 Celcuity 的近期和中期每股收益預期</strong>，包括對 <strong>2026 財年、2027 財年、2028 財年、2029 財年和 2026 年第四季度</strong> 的低預期，表明對持續虧損的預期，直到最終盈利。</li>
<li>消極情緒：投資者情緒似乎也受到影響，因為有報道稱 Celcuity 的股票在 <strong>試驗結果讓一些投資者失望後下跌</strong>，儘管其他報道將晚期乳腺癌數據描述為潛在強勁或 “改變實踐”。ASCO26：Celcuity 因試驗讓投資者失望而受到懲罰。</li>
</ul>
<h2>內部活動</h2>
<p>在其他 Celcuity 新聞中，董事 David Dalvey 於 5 月 4 日星期一出售了 25,000 股公司的股票。該股票以平均價格 140.68 美元出售，總價值為 3,517,000.00 美元。出售後，該董事持有 65,000 股公司的股票，價值 9,144,200 美元。這筆交易代表其持倉減少了 27.78%。該交易已在向美國證券交易委員會的法律文件中披露，文件可在此鏈接查看。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，董事 Richard E. Buller 於 5 月 4 日星期一出售了 9,000 股公司的股票。該股票以平均價格 140.46 美元出售，總價值為 1,264,140.00 美元。完成出售後，該董事直接持有 6,760 股公司的股票，價值約 949,509.60 美元。這筆交易代表其持倉減少了 57.11%。該出售的披露信息可在美國證券交易委員會的文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去的九十天裏，內部人士出售了價值 5,111,950 美元的 37,000 股公司股票。內部人士持有公司 13.33% 的股票。</p>
<h2>分析師評級調整</h2>
<p>CELC 最近成為多份研究報告的主題。富國銀行將 Celcuity 的目標價從 183.00 美元下調至 166.00 美元，並在週三的報告中對該股票設定了 “超配” 評級。Guggenheim 在週三的報告中重新發布了對 Celcuity 股票的 “買入” 評級。Wolfe Research 在 3 月 12 日的報告中重新發布了 “跑贏大盤” 評級，並設定了 110.00 美元的目標價。HC Wainwright 在 6 月 3 日的報告中將 Celcuity 的目標價從 185.00 美元下調至 145.00 美元，並對該股票設定了 “買入” 評級。最後，Citizens Jmp 在 5 月 4 日的報告中將 Celcuity 的目標價從 150.00 美元上調至 160.00 美元，並給予該股票 “市場跑贏大盤” 評級。十一位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat，Celcuity 的平均評級為 “適度買入”，平均目標價為 152.09 美元。</p>
<p><strong>閲讀我們關於 CELC 的最新報告</strong></p>
<h2>Celcuity 股票表現</h2>
<p>NASDAQ:CELC 週一開盤價為 88.28 美元。該公司的 50 日移動平均價格為 122.01 美元，200 日移動平均價格為 111.52 美元。Celcuity, Inc. 的 12 個月最低價為 11.27 美元，最高價為 151.02 美元。該股票的市值為 43.1 億美元，市盈率為 -22.64，貝塔值為 0.10。公司快速比率為 12.31，流動比率為 12.31，債務與股本比率為 6.04。</p>
<p>Celcuity (NASDAQ:CELC - 獲取免費報告) 最近一次發佈季度財報是在 5 月 14 日星期四。公司報告該季度每股收益為 -0.97 美元，超出市場普遍預期的 -1.07 美元，超出幅度為 0.10 美元。整體來看，股票分析師預測 Celcuity, Inc. 本財年的每股收益將為 -3.69。</p>
<h2>關於 Celcuity</h2>
<p>(免費報告)</p>
<p>Celcuity, Inc 是一家臨牀階段的生物技術公司，專注於精準腫瘤學診斷。該公司開發和商業化預測性生物標誌物檢測，旨在識別哪些患者最有可能從靶向癌症療法中受益。通過將腫瘤細胞的功能性分析與分子分析相結合，Celcuity 力求優化治療選擇，提高實體腫瘤患者的治療效果。</p>
<p>Celcuity 的專有平台通過使用外源性檢測評估腫瘤細胞對各種治療藥物的敏感性，測量 DNA 損傷反應和其他關鍵通路。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Celcuity 更好</li>
<li>這三隻保險股創下 52 周新高：還有買入的機會嗎？</li>
<li>三隻股價低於 20 美元的股票，適合在更廣泛的市場反彈前買入</li>
<li>Petco 面臨激烈競爭，但勢頭正在增強</li>
<li>鎖定效應是真實存在的——這三家建築商正在押注於此</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Celcuity 嗎？</h2>
<p>在考慮 Celcuity 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在買入的股票，而 Celcuity 並不在名單上。</p>
<p>雖然 Celcuity 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>在這裏查看這五隻股票</p>

CELC

<p>Geode Capital Management LLC 在第四季度將其在 Celcuity, Inc. (NASDAQ:CELC) 的持股增加了 8.4%，增持了 64,213 股，總持股達到 830,684 股，價值約為 8290 萬美元。其他機構投資者，包括 EverSource Wealth Advisors 和 Tower Research Capital 也擴大了他們的持倉。同時，內部人士 David Dalvey 和 Richard Buller 根據 10b5-1 計劃出售了股份。分析師的情緒仍然不一，HC Wainwright 維持買入評級，儘管下調了每股收益預期，而富國銀行則下調了其目標股價</p>

<p>Geode Capital Management LLC lifted its position in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 830,684 shares of the company's stock after acquiring an additional 64,213 shares during the quarter. Geode Capital Management LLC owned approximately 1.80% of Celcuity worth $82,872,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Geode Capital Management LLC 在最近向美國證券交易委員會提交的 13F 報告中表示，在第四季度將其在 Celcuity, Inc.（NASDAQ:CELC - 免費報告）股票中的持倉提高了 8.4%。該公司在本季度額外收購了 64,213 股後，持有 830,684 股 Celcuity 的股票。到最近一個季度末，Geode Capital Management LLC 擁有約 1.80% 的 Celcuity，價值 82,872,000 美元。</p>
</div><ul>
<li>3 Stocks You’ll Wish You Bought Before 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>你會希望在 2026 年之前購買的 3 只股票</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in CELC. EverSource Wealth Advisors LLC grew its stake in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock worth $34,000 after acquiring an additional 319 shares during the period. US Bancorp DE grew its stake in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company's stock worth $35,000 after acquiring an additional 143 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock worth $35,000 after acquiring an additional 1,167 shares during the period. Ogorek Anthony Joseph NY ADV grew its stake in shares of Celcuity by 19.7% during the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company's stock worth $66,000 after acquiring an additional 109 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of Celcuity by 211.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock worth $74,000 after acquiring an additional 3,766 shares during the period. Institutional investors own 63.33% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也對其在 CELC 的持倉進行了調整。EverSource Wealth Advisors LLC 在第四季度將其在 Celcuity 的股份增加了 1,329.2%。EverSource Wealth Advisors LLC 現在擁有 343 股該公司的股票，價值 34,000 美元，此前在此期間額外收購了 319 股。US Bancorp DE 在第三季度將其在 Celcuity 的股份增加了 25.4%。US Bancorp DE 現在擁有 706 股該公司的股票，價值 35,000 美元，此前在此期間額外收購了 143 股。BNP Paribas Financial Markets 在第二季度將其在 Celcuity 的股份增加了 78.9%。BNP Paribas Financial Markets 現在擁有 2,647 股該公司的股票，價值 35,000 美元，此前在此期間額外收購了 1,167 股。Ogorek Anthony Joseph NY ADV 在第四季度將其在 Celcuity 的股份增加了 19.7%。Ogorek Anthony Joseph NY ADV 現在擁有 662 股該公司的股票，價值 66,000 美元，此前在此期間額外收購了 109 股。最後，Tower Research Capital LLC TRC 在第二季度將其在 Celcuity 的股份增加了 211.2%。Tower Research Capital LLC TRC 現在擁有 5,549 股該公司的股票，價值 74,000 美元，此前在此期間額外收購了 3,766 股。機構投資者持有該公司 63.33% 的股票。</p>
</div><h2>Key Celcuity News</h2>
<div class="lb-trans"><h2>Celcuity 關鍵新聞</h2>
</div><p>Here are the key news stories impacting Celcuity this week:</p>
<div class="lb-trans"><p>以下是本週影響 Celcuity 的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright maintained a <strong>Buy</strong> rating and a <strong>$145 price target</strong> on Celcuity, and its longer-term forecasts still imply meaningful profitability potential by 2028-2030.</li>
<li>Neutral Sentiment: The company also announced an <strong>upsized $500 million convertible senior notes offering due 2032</strong>, which improves funding for development but also raises dilution concerns for shareholders. Celcuity Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032</li>
<li>Neutral Sentiment: Celcuity expanded its <strong>Phase 3 VIKTORIA-2</strong> trial to include endocrine-sensitive breast cancer patients, a development that could broaden the market opportunity if the study continues to progress well. Celcuity Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients</li>
<li>Negative Sentiment: HC Wainwright <strong>cut near- and medium-term EPS estimates</strong> for Celcuity, including lower projections for <strong>FY2026, FY2027, FY2028, FY2029, and Q4 2026</strong>, signaling expectations for continued losses before eventual profitability.</li>
<li>Negative Sentiment: Investor sentiment also appears to have been hurt by reports that Celcuity shares fell after <strong>trial results disappointed some investors</strong>, even though other coverage described the late-stage breast cancer data as potentially strong or “practice-changing.” ASCO26: Celcuity punished as trial disappoints investors</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：HC Wainwright 維持對 Celcuity 的 <strong>買入</strong> 評級，並設定 <strong>145 美元的目標價</strong>，其長期預測仍暗示到 2028-2030 年具有顯著的盈利潛力。</li>
<li>中性情緒：該公司還宣佈了一項 <strong>增大至 5 億美元的可轉換高級票據發行，截止日期為 2032 年</strong>，這改善了開發資金，但也引發了對股東稀釋的擔憂。Celcuity 宣佈增大公共發行 0.250% 可轉換高級票據的定價，截止日期為 2032 年。</li>
<li>中性情緒：Celcuity 將其 <strong>第三階段 VIKTORIA-2</strong> 試驗擴展至包括內分泌敏感型乳腺癌患者，如果研究繼續順利推進，這一發展可能會擴大市場機會。Celcuity 擴展第三階段 VIKTORIA-2 試驗以包括內分泌敏感型乳腺癌患者。</li>
<li>消極情緒：HC Wainwright <strong>下調了 Celcuity 的近期和中期每股收益預期</strong>，包括對 <strong>2026 財年、2027 財年、2028 財年、2029 財年和 2026 年第四季度</strong> 的低預期，表明對持續虧損的預期，直到最終盈利。</li>
<li>消極情緒：投資者情緒似乎也受到影響，因為有報道稱 Celcuity 的股票在 <strong>試驗結果讓一些投資者失望後下跌</strong>，儘管其他報道將晚期乳腺癌數據描述為潛在強勁或 “改變實踐”。ASCO26：Celcuity 因試驗讓投資者失望而受到懲罰。</li>
</ul>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other Celcuity news, Director David Dalvey sold 25,000 shares of the firm's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director owned 65,000 shares of the company's stock, valued at $9,144,200. This trade represents a 27.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 37,000 shares of company stock worth $5,111,950. Insiders own 13.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Celcuity 新聞中，董事 David Dalvey 於 5 月 4 日星期一出售了 25,000 股公司的股票。該股票以平均價格 140.68 美元出售，總價值為 3,517,000.00 美元。出售後，該董事持有 65,000 股公司的股票，價值 9,144,200 美元。這筆交易代表其持倉減少了 27.78%。該交易已在向美國證券交易委員會的法律文件中披露，文件可在此鏈接查看。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，董事 Richard E. Buller 於 5 月 4 日星期一出售了 9,000 股公司的股票。該股票以平均價格 140.46 美元出售，總價值為 1,264,140.00 美元。完成出售後，該董事直接持有 6,760 股公司的股票，價值約 949,509.60 美元。這筆交易代表其持倉減少了 57.11%。該出售的披露信息可在美國證券交易委員會的文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去的九十天裏，內部人士出售了價值 5,111,950 美元的 37,000 股公司股票。內部人士持有公司 13.33% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>CELC has been the topic of a number of recent research reports. Wells Fargo &amp; Company dropped their price objective on Celcuity from $183.00 to $166.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday. Guggenheim reissued a &#34;buy&#34; rating on shares of Celcuity in a report on Wednesday. Wolfe Research reissued an &#34;outperform&#34; rating and set a $110.00 price objective on shares of Celcuity in a report on Thursday, March 12th. HC Wainwright dropped their price objective on Celcuity from $185.00 to $145.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, June 3rd. Finally, Citizens Jmp increased their price objective on Celcuity from $150.00 to $160.00 and gave the stock a &#34;market outperform&#34; rating in a report on Monday, May 4th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Celcuity has an average rating of &#34;Moderate Buy&#34; and an average price target of $152.09.</p>
<div class="lb-trans"><p>CELC 最近成為多份研究報告的主題。富國銀行將 Celcuity 的目標價從 183.00 美元下調至 166.00 美元，並在週三的報告中對該股票設定了 “超配” 評級。Guggenheim 在週三的報告中重新發布了對 Celcuity 股票的 “買入” 評級。Wolfe Research 在 3 月 12 日的報告中重新發布了 “跑贏大盤” 評級，並設定了 110.00 美元的目標價。HC Wainwright 在 6 月 3 日的報告中將 Celcuity 的目標價從 185.00 美元下調至 145.00 美元，並對該股票設定了 “買入” 評級。最後，Citizens Jmp 在 5 月 4 日的報告中將 Celcuity 的目標價從 150.00 美元上調至 160.00 美元，並給予該股票 “市場跑贏大盤” 評級。十一位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat，Celcuity 的平均評級為 “適度買入”，平均目標價為 152.09 美元。</p>
</div><p><strong>Read Our Latest Report on CELC</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CELC 的最新報告</strong></p>
</div><h2>Celcuity Stock Performance</h2>
<div class="lb-trans"><h2>Celcuity 股票表現</h2>
</div><p>NASDAQ:CELC opened at $88.28 on Monday. The business's 50-day moving average price is $122.01 and its two-hundred day moving average price is $111.52. Celcuity, Inc. has a twelve month low of $11.27 and a twelve month high of $151.02. The stock has a market cap of $4.31 billion, a P/E ratio of -22.64 and a beta of 0.10. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.</p>
<div class="lb-trans"><p>NASDAQ:CELC 週一開盤價為 88.28 美元。該公司的 50 日移動平均價格為 122.01 美元，200 日移動平均價格為 111.52 美元。Celcuity, Inc. 的 12 個月最低價為 11.27 美元，最高價為 151.02 美元。該股票的市值為 43.1 億美元，市盈率為 -22.64，貝塔值為 0.10。公司快速比率為 12.31，流動比率為 12.31，債務與股本比率為 6.04。</p>
</div><p>Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.10. As a group, equities analysts predict that Celcuity, Inc. will post -3.69 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Celcuity (NASDAQ:CELC - 獲取免費報告) 最近一次發佈季度財報是在 5 月 14 日星期四。公司報告該季度每股收益為 -0.97 美元，超出市場普遍預期的 -1.07 美元，超出幅度為 0.10 美元。整體來看，股票分析師預測 Celcuity, Inc. 本財年的每股收益將為 -3.69。</p>
</div><h2>About Celcuity</h2>
<div class="lb-trans"><h2>關於 Celcuity</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.</p>
<div class="lb-trans"><p>Celcuity, Inc 是一家臨牀階段的生物技術公司，專注於精準腫瘤學診斷。該公司開發和商業化預測性生物標誌物檢測，旨在識別哪些患者最有可能從靶向癌症療法中受益。通過將腫瘤細胞的功能性分析與分子分析相結合，Celcuity 力求優化治療選擇，提高實體腫瘤患者的治療效果。</p>
</div><p>Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.</p>
<div class="lb-trans"><p>Celcuity 的專有平台通過使用外源性檢測評估腫瘤細胞對各種治療藥物的敏感性，測量 DNA 損傷反應和其他關鍵通路。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Celcuity</li>
<li>These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?</li>
<li>3 Stocks Under $20 to Buy Before a Broader Market Rally</li>
<li>Petco Faces Tough Competition, But Momentum Is Building</li>
<li>The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Celcuity 更好</li>
<li>這三隻保險股創下 52 周新高：還有買入的機會嗎？</li>
<li>三隻股價低於 20 美元的股票，適合在更廣泛的市場反彈前買入</li>
<li>Petco 面臨激烈競爭，但勢頭正在增強</li>
<li>鎖定效應是真實存在的——這三家建築商正在押注於此</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CELC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celcuity Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Celcuity 嗎？</h2>
</div><p>Before you consider Celcuity, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Celcuity 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在買入的股票，而 Celcuity 並不在名單上。</p>
</div><p>While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Celcuity 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Geode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELC

Market Beat

Celcuity

美國合眾銀行

法國巴黎銀行(ADR)

富國銀行

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Geode Capital Management LLC 購買了 Celcuity, Inc.的 64,213 股股票 $CELC